LC INTERFACE FOR ACCELERATOR MASS SPECTROMETRY

该项目的目标是开发一种新的，超灵敏的 用于生物医学研究的分析工具， 液相色谱（LC）的分离能力， 加速器质谱（AMS）的灵敏度。这项新技术， 称为LC-AMS，将促进生物分子标记的研究 用碳14或氚做燃料AMS是一个强大的检测工具， 14 C和3 H在环境毒理学和人类致癌研究中的应用。 对于14 C，AMS具有比液体闪烁高1000倍的灵敏度 衰变计数，允许定量阿托摩尔（10[-18]摩尔），或 更小的样品。目前，使用AMS分析生物样品 受到高度专业化的样品制备要求的限制 与标准色谱仪不兼容的程序。的 第一阶段的目标是开发实时耦合技术， 一个LC到AMS系统的输入，导致施工， 在第二阶段测试LC-AMS接口。该接口将与 NSI开发的紧凑型生物医学AMS系统， 首次展示了对来自 使用AMS的LC。它也将适合与其他现有的 AMS系统。 拟议的商业应用： 生物医学LC-AMS系统具有广泛的商业应用前景 毒理学和新药研究。有了这台仪器， 可以使用三种药物进行药物代谢和动力学研究 比现在的示踪剂活性低几个数量级。成本 LC-AMS系统的尺寸将与安装在 大型医学研究中心。LC-AMS接口还将具有 商业市场作为一个独立的工具， 任何现有的AMS系统的生物医学用途。

The goal of this project is the development of a new, ultra-sensitive analytical tool for biomedical research that couples the precision separation capabilities of liquid chromatography (LC) with the detection sensitivity of accelerator mass spectrometry (AMS). This new technique, known as LC-AMS, will promote the study of biological molecules labeled with carbon-14 or tritium. AMS is a powerful tool for the detection of 14C and 3H in environmental toxicology and human carcinogenesis research. For 14C, AMS has a 1000-fold higher sensitivity than liquid scintillation decay counting, allowing the quantitation of attomole (10[-18] mole), or smaller, samples. Presently, the analysis of biological samples using AMS is limited by the requirement for highly specialized sample preparation procedures which are not compatible with standard chromatographs. The goal of Phase I is to develop techniques for the real-time coupling of a LC to the input of an AMS system, leading to the construction and testing of a LC-AMS interface in Phase II. This interface will be coupled to a compact biomedical AMS system developed by NSI in order to demonstrate, for the first time, the detection of labeled molecules from a LC using an AMS. It will also be suitable for use with other existing AMS systems. PROPOSED COMMERCIAL APPLICATIONS: The biomedical LC-AMS system will have widespread commercial applications in toxicology and new drug research. With this instrument, it will be possible to conduct drug metabolism and kinetics studies using three orders-of-magnitude less tracer activity than is possible today. The cost and size of the LC-AMS system will be compatible with installation at major medical research centers. The LC-AMS interface will also have a commercial market as a stand-alone instrument which will allow conversion of any existing AMS system to biomedical use.